
The global system for discovering new cancer drugs is broken. It is failing to turn dramatic scientific advances into enough …

Merck and Eisai are teaming up for collaborative trials to test the effects of using combinations of each company’s oncology …

The FDA has approved Bristol-Myers Squibb’s Opdivo (nivolumab) for the treatment of patients with metastatic squamous non-small cell lung cancer …

There are plenty of advances in oncology treatments to be excited about – from immunotherapy to cancer vaccines and monoclonal …

GlaxoSmithKline’s planned major assets swap with Novartis has completed today as was predicted last week. Both firms announced the overhaul …

According to a new study women who undergo hormone replacement therapy nearly double their risk of developing ovarian cancer. Findings …
Roche will be celebrating after its investigational cancer drug MPDL3280A has been fast-tracked by the FDA for the second time. …

Roche has posted a mixed bag of financial results complemented only by strong growth in its oncology and immunology divisions. …

The UK is making a £30 million R&D investment into a promising new type of cancer treatment and is to …

Boehringer Ingelheim will help Sanofi extend its manufacturing capabilities for biologics in a new alliance, the companies have announced. Boehringer’s …

Lilly will test some of its compounds in combination with rival cancer drugs from Bristol-Myers Squibb and Merck, the companies …

Evotec and Sanofi have entered negotiations for a major multi-component strategic alliance worth around €250 million over the next five …

Patients are still pointlessly dying of lung cancer due to a ‘postcode lottery’ of services according to new results from …

The state of cancer services in Wales has come under increased scrutiny this week as the country’s ability to provide …

A group of oesophageal cancer patients can increase their survival by six months or more if treated with AstraZeneca’s Iressa, …